On June 3, 2026, the U.S. FDA issued the "Digital Presence for Medical Devices Guidance v2.1," bringing corporate websites into a more direct scope of compliance review. According to disclosed information, all Chinese companies exporting medical devices to the United States not only need to consider marketing and brand expression in their external digital presentation, but must also provide an English compliance statement in a prominent position on their official websites, especially on their Chinese main sites. This change deserves close attention from medical device export enterprises, regulatory registration teams, website operations personnel, and related digital service providers, because its impact no longer remains at the level of information display, but is directly linked to FDA on-site inspections and EUA renewals.

What requirements are clarified in this guidance update

Confirmed information shows that the U.S. FDA issued the "Digital Presence for Medical Devices Guidance v2.1" on June 3, and explicitly requires all Chinese companies exporting medical devices to the United States to provide an English compliance statement in a prominent position on their official websites, including their Chinese main sites.

This English compliance statement should include the following: 510(k)/De Novo/MDR status, a QSR820 certification summary, and a UDI link.

At the same time, confirmed information also indicates that if the above requirements are not met, companies will face consequences affecting FDA on-site inspections and EUA renewals. Looking at the matter itself, this means that the multilingual architecture of corporate websites has been given clearer compliance requirements and is no longer merely serving a display function.

The impact is extending from website pages to business coordination

For export enterprises, the official website has become a compliance touchpoint

From an analysis perspective, companies that directly export medical devices to the U.S. market will be the first to be affected. The reason is that this requirement directly targets "Chinese companies exporting medical devices to the United States," and the scope of constraint is not limited to English websites, but also covers Chinese main sites. The impact will mainly be reflected in areas such as official website information release, disclosure of regulatory status, cross-language content consistency, and preparation for external audits. The change companies need to pay attention to is not just "whether there is an English page," but whether the official website can accurately present the required content in a prominent position.

For registration, regulatory, and quality teams, public wording needs to be more rigorous

From a business role perspective, registration, regulatory, and quality-related teams will also be significantly affected. This is because the compliance statement involves 510(k)/De Novo/MDR status, a QSR820 certification summary, and a UDI link, all of which have clear compliance attributes. From an analytical point of view, relevant teams need to pay closer attention to the consistency between public information on the official website and internal regulatory materials, so as to avoid discrepancies between website wording and actual status, which could in turn affect audit communication or renewal arrangements.

For website development and multilingual service providers, delivery standards will change

From an observation perspective, website development, content operations, and multilingual service providers serving medical device companies will also face new delivery requirements. In the past, many official website projects focused more on brand presentation, product introduction, and inquiry conversion, but the signal released by this update is that website structure, page hierarchy, and language version management are being brought into compliance considerations. The focus that relevant service providers need to pay attention to will shift from page aesthetics and basic translation to compliance information carrying, prominent position settings, and subsequent update mechanisms.

For channel and procurement communication processes, information transparency requirements are increasing

From an industry perspective, channel partners, procurement parties, and business counterparts who need to quickly verify product compliance status may also be indirectly affected. Because public information on official websites is required to be more complete and more verifiable, the way companies respond during customer communication, qualification explanation, and document retrieval may be adjusted accordingly. The change that needs attention is that the website is no longer just an external publicity window, but may also become part of the preliminary verification process.

Which practical details companies should focus on now

First check whether the Chinese main site has a compliance entry point

From an analytical perspective, the first thing companies should focus on is not how many new pages to add, but whether the Chinese official website already has an English compliance statement entry in a "prominent position." Because this requirement specifically points to the Chinese main site, this means that setting relevant content only on the English site does not naturally equal meeting the requirement. Reviewing the existing official website structure should become a more practical first step.

Focus on verifying whether public content is consistent with actual status

What deserves more attention at present is that the information involved in the compliance statement is not ordinary promotional copy, but content directly related to regulatory status. When preparing 510(k)/De Novo/MDR status, a QSR820 certification summary, and a UDI link, companies need to distinguish between information that can be publicly expressed and internal materials, while maintaining consistency in external communication. The key here is not to "write more richly," but to "write accurately and keep it continuously updated."

Turn multilingual operations from a translation workflow into a compliance workflow

From an observation perspective, the practical requirement conveyed by this update is that companies need to re-understand how multilingual official websites are managed. In the past, many companies regarded multilingual pages as extended work for the marketing or brand department, but under this requirement, closer coordination is needed among official website English content, Chinese main site entry points, regulatory materials, and quality information. For companies, what needs to be established even more is an update responsibility system, review checkpoints, and a cross-department confirmation mechanism, rather than simply adding a paragraph of English explanation.

Pay attention to actual usage risks in audit and renewal scenarios

From a practical perspective, confirmed information has clearly mentioned that this requirement may affect FDA on-site inspections and EUA renewals. Therefore, companies need to pay attention to the actual role of website content in audit scenarios and prepare in advance how website information, internal documents, and external explanations connect with each other. From an analytical perspective, this kind of preparation is closer to a compliance contingency plan rather than ordinary information maintenance.

This is more like a forward shift of a digital compliance signal

From the editor's observation, this piece of news should not be understood merely as a website layout adjustment, but is more appropriately understood as regulation putting forward clearer compliance requirements for a company's "digital presence." The core change is that the official website is no longer just a platform carrying marketing communication content, but is also regarded as part of reflecting a company's compliance status.

Looking further, this development brings not only short-term practical pressure at the execution level, but also a certain long-term signal. In the short term, affected companies need to handle issues such as page setup, content preparation, and cross-department verification; in the long run, the management of official websites for medical device companies targeting overseas markets may increasingly emphasize verifiability, traceability, and alignment with regulatory context. However, based on currently known information, whether more detailed implementation standards will be formed later still needs continuous observation.

From display-oriented websites to compliance-oriented websites

Overall, the key point released by this FDA update is not whether companies have multilingual official websites, but whether the official website can undertake the function of compliance information disclosure. For Chinese companies exporting medical devices to the United States, this requirement is currently more appropriately understood as a compliance change that already has practical impact, especially as it will affect official website management, regulatory disclosure, and audit preparation.

Therefore, the industry's understanding of this information should not remain at the level of "adding a new English statement," but should recognize the business implication behind it: a company's digital external window is shifting from display orientation to compliance orientation. As for the subsequent scale of implementation, the speed of corporate adaptation, and the market's response, these still need to be continuously verified in conjunction with subsequent public information.

Basis of this article and directions for subsequent verification

This article is generated based on the news title, event occurrence time, and event summary provided by the user. The core basis includes: on June 3, 2026, the U.S. FDA issued the "Digital Presence for Medical Devices Guidance v2.1" and required Chinese companies exporting medical devices to the United States to provide an English compliance statement in a prominent position on their official websites. Relevant content includes 510(k)/De Novo/MDR status, a QSR820 certification summary, and a UDI link. Failure to meet the requirements may affect FDA on-site inspections and EUA renewals.

According to the common verification path for this type of industry news, follow-up can usually be continuously cross-checked with official announcements, corporate announcements, industry association information, authoritative media reports, and relevant standards or guidance documents. It should be noted that this input did not provide a specific official source link, so the exact official link still needs subsequent continuous verification. For industry participants, the directions that deserve more attention later include: whether official sources provide further explanatory statements, whether the actual implementation methods on corporate official websites tend toward standardization, and whether the enforcement standards for this requirement in audit and renewal scenarios become clearer.